SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) (&#34;Kazia,&#34; &#34;Kazia Therapeutics&#34; or the &#34;Company&#34;), a clinical-stage oncology company advancing therapies designed to

<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SYDNEY</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">June 2, 2026</span> /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow">Kazia Therapeutics Limited</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/KZIA">KZIA</a>) (&#34;Kazia,&#34; &#34;Kazia Therapeutics&#34; or the &#34;Company&#34;), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p>
<p xmlns="http://www.w3.org/1999/xhtml">&#34;James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following an extensive career in investment banking,&#34; said Dr. John Friend, CEO, Kazia Therapeutics. &#34;As we advance paxalisib and progress our pipeline, James&#39; expertise will be central to helping us capitalize on that momentum and continue building long-term value for patients and shareholders.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">Most recently, Mr. Levine served as Chief Financial Officer of Cardiff Oncology, a clinical-stage oncology company developing a PLK1 inhibitor therapy for solid tumors.  Prior to Cardiff Oncology, Mr. Levine served as CFO of Cidara Therapeutics, an antifungal and antiviral biotech company, where he led the financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals (Johnson &amp; Johnson). He also served as CEO of Verenium Corporation, an industrial biotech company, where he executed major asset sales for total proceeds of approximately $200 million, as well as Sapphire Energy, a human nutrition-focused biotech.</p><p xmlns="http://www.w3.org/1999/xhtml">Earlier in his career, Mr. Levine spent 12 years at Goldman Sachs &amp; Co. as a Managing Director advising pharmaceutical and biotech clients across the U.S. and Europe on financings, mergers and acquisitions and strategic transactions, including landmark deals such as the Glaxo Wellcome and SmithKline Beecham merger. Mr. Levine holds a Master of Business Administration degree from The Wharton School at the University of Pennsylvania.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;I am very excited to be joining Kazia as the Company advances paxalisib across multiple indications and builds out a promising pipeline targeting novel mechanisms of treatment resistance,&#34; added Mr. Levine. &#34;I look forward to working closely with the management team to help translate Kazia&#39;s scientific progress into strategic and financial outcomes as we approach what we expect to be a period of meaningful</p><p xmlns="http://www.w3.org/1999/xhtml">clinical and strategic milestones for the Company.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Kazia Therapeutics</b></p><p xmlns="http://www.w3.org/1999/xhtml">Kazia Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/KZIA">KZIA</a>) is an oncology-focused drug development company, based in Sydney, Australia. The Company&#39;s lead asset, paxalisib, is an investigational brain penetrant inhibitor of the PI3K/Akt /mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of 10 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval.  Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy.  Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.kaziatherapeutics.com" rel="nofollow">www.kaziatherapeutics.com</a> or follow us on X @KaziaTx.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements </b></p><p xmlns="http://www.w3.org/1999/xhtml">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;future,&#34; &#34;forward,&#34; &#34;anticipate,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;potential,&#34; or other similar words.  Any statement describing Kazia&#39;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the Company&#39;s expectations regarding its pipeline strategy and future clinical and strategic milestones; the anticipated contributions of Mr. Levine to the Company&#39;s business; and Kazia&#39;s plans to advance paxalisib and its broader oncology pipeline.  Such statements are based on Kazia&#39;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with: the development of early stage therapeutic programs; the conduct of clinical trials, including the ability to enroll patients and achieve anticipated enrollment targets; the preliminary nature of data from a small, open-label clinical study, which may not be predictive of later-stage clinical results; risks related to regulatory approvals; risks related to Kazia&#39;s reliance on third-party collaborators and clinical trial sites; risks related to the Company&#39;s ability to obtain, maintain and protect its intellectual property; risks related to the impact of global economic conditions; and risks related to Kazia&#39;s ability to maintain compliance with the applicable NASDAQ continued listing requirements and standards.  These and other risks and uncertainties are described more fully in Kazia&#39;s Annual Report on Form 20-F filed with the SEC, and in subsequent filings with the United States Securities and Exchange Commission.  Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law.  You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Media Contacts </b></p><p xmlns="http://www.w3.org/1999/xhtml">Michaela Fawcett / Molly Crawford<br xmlns="http://www.w3.org/1999/xhtml"></br>KCSA Strategic Communications<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:mfawcett@kcsa.com" target="_blank" rel="nofollow">mfawcett@kcsa.com</a> / <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:mcrawford@kcsa.com" target="_blank" rel="nofollow">mcrawford@kcsa.com</a> </p><p xmlns="http://www.w3.org/1999/xhtml" class="prntac">###</p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=CN73244&amp;sd=2026-06-02"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer-302787604.html" target="_blank">https://www.prnewswire.com/news-releases/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer-302787604.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Kazia Therapeutics Limited</p>

KZIA

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia appoints James Levine as CFO to support Paxalisib milestones

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) (&amp;#34;Kazia,&amp;#34; &amp;#34;Kazia Therapeutics&amp;#34; or the &amp;#34;Company&amp;#34;), a clinical-stage oncology company advancing therapies designed to</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kazia Therapeutics named James Levine as chief financial officer, effective June 1, 2026. Levine&#039;s 20+ years in biotech finance include CFO roles at Cardiff Oncology and Cidara Therapeutics, with major licensing and partnership experience. The hire potentially strengthens Kazia&#039;s capital strategy and transactional optionality as Paxalisib advances, potentially impacting funding or collaboration opportunities over the near to medium term.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kazia appoints James Levine as CFO, effective June 1, 2026.</li><li>Levine brings 20+ years in biotech finance, including CFO roles at Cardiff Oncology and Cidara Therapeutics.</li><li>Levine led major licensing and collaboration deals totaling $568M and $780M respectively.</li><li>Kazia aims to capitalize on Paxalisib milestones and its broader pipeline with enhanced financial strategy.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Kazia Therapeutics Limited (KZIA)</strong>: Appointment of James Levine as CFO; leadership change may influence financing strategy and strategic transactions as Paxalisib progresses.</li><li><strong>Cardiff Oncology, Inc. (CRDF)</strong>: Former CFO James Levine; demonstrates track record in biotech finance and strategic execution.</li><li><strong>Cidara Therapeutics, Inc. (CDTX)</strong>: Levine&#039;s prior CFO role; involved in large licensing and collaboration deals indicating potential for future Kazia partnerships.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category fits Corporate Developments as the article centers on a leadership change with potential strategic and financial implications for Kazia&#039;s pipeline and funding strategy.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>New CFO may enable faster capital raising or strategic collaborations.</li><li>No new Paxalisib clinical data announced; near-term stock reaction may be muted.</li><li>Improved financial leadership could support milestones and potential partnering discussions.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Appointment effective June 1, 2026.</li><li>Kazia Therapeutics Limited trades on NASDAQ as KZIA.</li><li>Paxalisib is the lead asset; Phase 2/3 GBM Agile study completed in 2024.</li><li>FDA Orphan Drug designation for glioblastoma: February 2018.</li><li>FDA Fast Track designation for glioblastoma: August 2020.</li><li>FTD for solid tumor brain metastases in combination with radiation therapy: July 2023.</li><li>Paxalisib licensed from Genentech in late 2016.</li><li>Levine previously CFO at Cardiff Oncology; led $568M Mundipharma licensing and $780M Janssen partnership at Cidara.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral-to-mildly bullish near-term; CFO appointment could unlock financing or partnerships as Paxalisib advances, with potential upside if new capital or deals emerge within 6–12 months.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SYDNEY</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">June 2, 2026</span> /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow">Kazia Therapeutics Limited</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/KZIA">KZIA</a>) (&#34;Kazia,&#34; &#34;Kazia Therapeutics&#34; or the &#34;Company&#34;), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p>
<p xmlns="http://www.w3.org/1999/xhtml">&#34;James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following an extensive career in investment banking,&#34; said Dr. John Friend, CEO, Kazia Therapeutics. &#34;As we advance paxalisib and progress our pipeline, James&#39; expertise will be central to helping us capitalize on that momentum and continue building long-term value for patients and shareholders.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">Most recently, Mr. Levine served as Chief Financial Officer of Cardiff Oncology, a clinical-stage oncology company developing a PLK1 inhibitor therapy for solid tumors.  Prior to Cardiff Oncology, Mr. Levine served as CFO of Cidara Therapeutics, an antifungal and antiviral biotech company, where he led the financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals (Johnson &amp; Johnson). He also served as CEO of Verenium Corporation, an industrial biotech company, where he executed major asset sales for total proceeds of approximately $200 million, as well as Sapphire Energy, a human nutrition-focused biotech.</p><p xmlns="http://www.w3.org/1999/xhtml">Earlier in his career, Mr. Levine spent 12 years at Goldman Sachs &amp; Co. as a Managing Director advising pharmaceutical and biotech clients across the U.S. and Europe on financings, mergers and acquisitions and strategic transactions, including landmark deals such as the Glaxo Wellcome and SmithKline Beecham merger. Mr. Levine holds a Master of Business Administration degree from The Wharton School at the University of Pennsylvania.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;I am very excited to be joining Kazia as the Company advances paxalisib across multiple indications and builds out a promising pipeline targeting novel mechanisms of treatment resistance,&#34; added Mr. Levine. &#34;I look forward to working closely with the management team to help translate Kazia&#39;s scientific progress into strategic and financial outcomes as we approach what we expect to be a period of meaningful</p><p xmlns="http://www.w3.org/1999/xhtml">clinical and strategic milestones for the Company.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Kazia Therapeutics</b></p><p xmlns="http://www.w3.org/1999/xhtml">Kazia Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/KZIA">KZIA</a>) is an oncology-focused drug development company, based in Sydney, Australia. The Company&#39;s lead asset, paxalisib, is an investigational brain penetrant inhibitor of the PI3K/Akt /mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of 10 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval.  Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy.  Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.kaziatherapeutics.com" rel="nofollow">www.kaziatherapeutics.com</a> or follow us on X @KaziaTx.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements </b></p><p xmlns="http://www.w3.org/1999/xhtml">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;future,&#34; &#34;forward,&#34; &#34;anticipate,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;potential,&#34; or other similar words.  Any statement describing Kazia&#39;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the Company&#39;s expectations regarding its pipeline strategy and future clinical and strategic milestones; the anticipated contributions of Mr. Levine to the Company&#39;s business; and Kazia&#39;s plans to advance paxalisib and its broader oncology pipeline.  Such statements are based on Kazia&#39;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with: the development of early stage therapeutic programs; the conduct of clinical trials, including the ability to enroll patients and achieve anticipated enrollment targets; the preliminary nature of data from a small, open-label clinical study, which may not be predictive of later-stage clinical results; risks related to regulatory approvals; risks related to Kazia&#39;s reliance on third-party collaborators and clinical trial sites; risks related to the Company&#39;s ability to obtain, maintain and protect its intellectual property; risks related to the impact of global economic conditions; and risks related to Kazia&#39;s ability to maintain compliance with the applicable NASDAQ continued listing requirements and standards.  These and other risks and uncertainties are described more fully in Kazia&#39;s Annual Report on Form 20-F filed with the SEC, and in subsequent filings with the United States Securities and Exchange Commission.  Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law.  You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Media Contacts </b></p><p xmlns="http://www.w3.org/1999/xhtml">Michaela Fawcett / Molly Crawford<br xmlns="http://www.w3.org/1999/xhtml"></br>KCSA Strategic Communications<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:mfawcett@kcsa.com" target="_blank" rel="nofollow">mfawcett@kcsa.com</a> / <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:mcrawford@kcsa.com" target="_blank" rel="nofollow">mcrawford@kcsa.com</a> </p><p xmlns="http://www.w3.org/1999/xhtml" class="prntac">###</p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=CN73244&amp;sd=2026-06-02"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer-302787604.html" target="_blank">https://www.prnewswire.com/news-releases/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer-302787604.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Kazia Therapeutics Limited</p>

Kazia Therapeutics named James Levine as chief financial officer, effective June 1, 2026. Levine's 20+ years in biotech finance include CFO roles at Cardiff Oncology and Cidara Therapeutics, with major licensing and partnership experience. The hire potentially strengthens Kazia's capital strategy and transactional optionality as Paxalisib advances, potentially impacting funding or collaboration opportunities over the near to medium term.

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News